Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Nowadays, there are still several unmet medical needs in the field of orthopaedic and trauma surgery leading to the incentive of finding alternative and innovative clinical therapeutics for the treatment of bone regeneration. For example, the entrapment of ...
The aim of the study is to evaluate the differences of protein binding of NAMI-A, a new ruthenium drug endowed with selective antimetastatic properties, and of cisplatin and to ascertain the possibility to use two drugs based on heavy metals in combination ...
With a view to develop drugs that could resist hydrolysis in aq. media,organometallic arene-capped ruthenium(II) 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (RAPTA) complexes bearing chelating carboxylate ligands have been prepd. and studied. The new com ...
The isolation and characterisation of natural products remains a challenge in chemistry owing to nature's magnificent diversity. Natural products or natural product derivatives have always been used in traditional medicine to treat a variety of diseases. T ...
The present invention relies on the moiré patterns generated when superposing a base layer made of base band patterns and a revealing line grating (revealing layer). The produced moiré patterns comprise an enlargement and a transformation of the individual ...
Development of new drugs to treat tuberculosis (TB) faces even more constraints than the development of therapeutic agents for other diseases. This is due, in part, to intrinsic properties of the tubercle bacillus, such as its slow growth, phenotypic drug ...
A review. The systematic development of the RAPTA family of organometallic ruthenium(II) anticancer drugs contg. a monodentate 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane ligand and a h6-arene ligand is described. ...
Personalized therapy requires accurate and frequent monitoring of drugs metabolic response in living organisms during drug treatments. In case of high risk side effects, e.g. therapies with interfering anti-cancer molecules cocktails, direct monitoring of ...
Nanoparticles show several interesting new physical and biological properties and therefore play an increasing role in pharmaceutics and medicine. For more than 30 years this research field has been developing slowly but steadily from physical and biologic ...
Swiss Medical Publishers Ltd / EMH Swiss Medical Publishers2010
Availability of an ultra-short-course drug regimen capable of curing patients with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because immediate prospects for novel treatment-shortening drugs remain uncertain, we examined ...
